Squamous cell carcinoma head and neck is the sixth most common cancer worldwide and. 1 Multimodality therapies have been advocated for locoregional relapse or metastatic disease. 2 Combination therapy with lenvatinib has been considered to overcome resistance and improve the efficacy. 3 In a recent study of lenvatinib and pembrolizumab conducted in heavily pretreated recurrent and metastatic head and neck cancer, the median overall survival OS was 6.2 months, and the median progression-free survival (PFS) was 4.6 months. 4
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.